MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

Why Are Analysts So Bullish on Sagimet Biosciences (SGMT)

2 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why is Goldman Sachs so Bullish on Gold

2 months ago

Why Are Wall Street Analysts Bullish on These Three Stocks

1 months ago

Why Are Analysts Bullish on Cullinan Therapeutics (CGEM)

2 months ago

Why Are Analysts Bullish on Strata Critical Medical (SRTA) Despite Cathie Wood's Exit

1 months ago

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences secured $175M in gross equity proceeds during April 2026. The company plans to initiate a Phase 3 trial for denifanstat in acne patients during 2H 2026, with current cash reserves ...

SGMT

Stock News•2 weeks ago

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Sagimet Biosciences Inc. (SGMT) shares face a potential 241.8% upside based on the mean of current Wall Street analyst price targets. This outlook is supported by a consensus among analysts to raise e...

SGMT

Stock News•3 weeks ago

Is It Worth Investing in Super Group (SGHC) (SGHC) Based on Wall Street's Bullish Views?

Super Group (SGHC) faces investor scrutiny as market participants weigh the influence of sell-side analyst ratings on stock performance. The current discourse examines whether brokerage-firm recommend...

SGHC

Stock News•3 weeks ago

ASST Has a Strong Buy Rating and No Path to Profitability for 3 Years. Buy It Anyway?

Srive (NASDAQ:ASST) maintains a 'Strong Buy' analyst rating despite projections showing no path to profitability for the next three years. The disconnect between bullish sentiment and fundamental fina...

ASST